<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-435
Date of Submission: 2025-01-27

This report was submitted by a Pharmacist from Cook LLC Medical Center concerning patient ANON-PX-3493. The subject is an adult female with a significant medical history including type 2 diabetes, seasonal allergies, osteoarthritis, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Intramuscular route at a dosage of 16mg, initiated on 2024-12-15 for Neuropathic pain and discontinued on 2025-01-24.

On approximately 2025-01-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Diarrhea, Pruritus. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed watch and advised hundred. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed provide and advised own. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Somebody they difference member. Quite best least. Lead bed move institution choice they.</data>
report_id: ADR-2025-435
report_date: '2025-01-27'
patient_details:
  patient_id: ANON-PX-3493
  gender: Female
  relevant_history:
  - type 2 diabetes
  - seasonal allergies
  - osteoarthritis
  - atrial fibrillation
suspected_drugs:
- drug_name: Gabapentin
  dosage: 16mg
  route_of_administration: Intramuscular
  start_date: '2024-12-15'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2025-01-24'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2025-01-01'
  severity: Mild
  outcome: Fatal
  intervention_required: false
- symptom_name: Diarrhea
  onset_date: '2025-01-01'
  severity: Moderate
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed watch and advised hundred.
- symptom_name: Pruritus
  onset_date: '2025-01-01'
  severity: Life-threatening
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed provide and advised own.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
reporting_facility: Cook LLC Medical Center
reporter_type: Pharmacist
notes: Somebody they difference member. Quite best least. Lead bed move institution
  choice they.
